Web Results

www.finnegan.com/images/content/1/3/v2/134216/2016.08.pdf

IN THE UNITED STATES DISTRICT COURT. FOR THE DISTRICT OF DELAWARE. SANOFI and SANOFI-AVENTIS U.S. LLC,. Plaintiffs, v. GLENMARK PHARMACEUTICALS INC.,. USA, et al.,. Defendants. Civil Action No. 14-264- RGA. (CONSOLIDATED). TRIAL OPINION. Jack B. Blumenfeld, Esq., Derek J. Fahnestock, ...

search.rpxcorp.com/litigation_documents/12379480

Sanofi-Aventis U.S. LLC and Genzyme Corporation (collectively, “Sanofi”), and. Regeneron Pharmaceuticals .... trials, with patients receiving treatment with AMG- 317 reporting only small improvements relative to placebo. ... See Corren, et al., “ A Randomized, Controlled, Phase 2 Study of AMG 317, an IL-. 4α Antagonist, in ...

law.justia.com/cases/federal/district-courts/new-jersey/njdce/2011

Free Database of 2011 District of New Jersey US Federal District Court Case Law, Court Opinions & Decisions from Justia.

petrieflom.law.harvard.edu/assets/publications/Sachs_Rachel_in_Sanofi_Federal_Appeal_2017.pdf

Jan 13, 2017 ... v. SANOFI, SANOFI-AVENTIS U.S. LLC, AVENTISUB LLC, f/d/b/a AVENTIS. PHARMACEUTICALS INC., and REGENERON PHARMACEUTICALS, INC., ... Sanofi is the parent corporation of sanofi-aventis and. Aventisub LLC. Regeneron Pharmaceuticals, Inc. has no parent corporation. Sanofi, through ...

www2.ca3.uscourts.gov/opinarch/142017p.pdf

May 4, 2016 ... UNITED STATES COURT OF APPEALS. FOR THE THIRD CIRCUIT. ______. No. 14-2017. ______. EISAI, INC.,. Appellant v. SANOFI AVENTIS U.S., LLC;. SANOFI U.S. SERVICES, INC. f/k/a. Sanofi-Aventis U.S. Inc. On Appeal from the United States District Court for the District of New Jersey. (D. C. Civil ...

www.cafc.uscourts.gov/sites/default/files/opinions-orders/17-1480.Opinion.10-2-2017.1.PDF

Oct 5, 2017 ... Appellants Sanofi, Aventisub LLC, Regeneron Phar- maceuticals Inc., and Sanofi -Aventis U.S., LLC (collective- ly, “Appellants”) appeal from a final judgment of the district court holding U.S. Patent Nos. 8,829,165 (“'165 patent”) and 8,859,741 (“' 741 patent”) not invalid and granting a permanent injunction ...

www.patentdocs.org/new_biotech_cases

Sep 4, 2016 ... Genzyme Corp. et al. v. Zydus Pharmaceuticals (USA) Inc. 1:16-cv-00540; filed June 29, 2016 in the District Court of Delaware. Plaintiffs: Genzyme Corp.; Sanofi -Aventis U.S. LLC Defendant: Zydus Pharmaceuticals (USA) Inc. Infringement of U.S. Patent Nos. 7,897,590 ("Methods to mobilize progenitor/stem ...

www.bakerbotts.com/ideas/publications/2016/05/third-circuit-rejects-single

May 11, 2016 ... On May 4, 2016, the U.S. Court of Appeals for the Third Circuit announced its decision in Eisai, Inc. v. Sanofi Aventis U.S., LLC,1 rejecting antitrust claims predicated on a supplier's market-share discount program and other promotional tactics. While the court's decision adds some definition to an amorphous ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC3013554

Bridgewater, NJ: Dermik Laboratories, a business of sanofi-aventis U.S., LLC; 2009. 4. Gogolewski S, Jovanovic M, Perren SM, et al. Tissue response and in- vivo degradation of selected polyhydroxyacids: polylactides (PLA), poly(3- hydroxybutyrate) (PHB), and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB/ VA) J ...